Brentuximab vedotin in refractory or relapsed Peripheral T-cell Lymphomas: The French named patient program experience in 56 patients

Mathilde Lamarque, Céline Bossard, Adrien Contejean, Pauline Brice, Marie Parrens, Steven Le Gouill, Josette Brière, Reda Bouabdallah, Danielle Canioni, Herve’ Tilly, Brigitte Bouchindhomme, Emmanuel Bachy, Richard Delarue, Corinne Haioun, and Philippe Gaulard

Disclosures: There is no conflict of interest in this report.

Contributions: Conception and design: Richard Delarue, Celine Bossard, Herve Tilly, Corinne Haioun and Philippe Gaulard. Pathological review and CD30 assessment: Celine Bossard, Marie Parrens, Philippe Gaulard. Collection and assembly of data: all authors. Data analysis and interpretation: Mathilde Lamarque, Celine Bossard, Adrien Contejean, Corinne Haioun, Philippe Gaulard. Manuscript writing: all authors. Final approval of manuscript: all authors. Provision of study materials or patients: all authors.